Summary
Zoetis Inc. (ZTS) has filed an 8-K report detailing significant executive leadership changes. The most prominent announcement is the appointment of James Saccaro as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro brings substantial experience from GE HealthCare and Baxter International and will be responsible for Zoetis's global finance functions and Global Manufacturing and Supply operations. Concurrently, the company announced the departure of Wetteny Joseph from his role as Executive Vice President and Chief Financial Officer. Mr. Joseph will transition to a non-executive advisory role through February 28, 2027, with his departure not related to any disagreements. These executive changes suggest a strategic shift in financial and operational leadership for Zoetis.
Key Highlights
- 1James Saccaro appointed as EVP, CFO, and COO, effective August 17, 2026.
- 2Mr. Saccaro's responsibilities will include global finance, capital allocation, financial strategy, investor engagement, and overseeing Global Manufacturing and Supply.
- 3Mr. Saccaro previously served as CFO of GE HealthCare and Baxter International.
- 4Mr. Saccaro's compensation package includes a base salary of $1,000,000, target annual incentive of 100% of base salary, and a target long-term incentive opportunity of $5,000,000.
- 5Mr. Saccaro will receive a one-time make-whole award of $6,250,000 in RSUs and a $1,250,000 cash award.
- 6Wetteny Joseph, the outgoing CFO, will transition to an advisory role until February 28, 2027.
- 7Mr. Joseph's departure is not due to any disagreements with the company.